Mary Wilson
Well-known member
Published:March 30, 2021
DOI: https://doi.org/10.1016/S0140-6736(21)00628-0
Katherine R W Emary, FRCPath *, Tanya Golubchik, PhD *, Parvinder K Aley, DPhil , Cristina V Ariani, PhD , Brian Angus, MD , Sagida Bibi, PhD et al. Show all authors
Summary
Background
A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the e cacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant.
Methods
Volunteers (aged ?18 years) who were enrolled in phase 2/3 vaccine e cacy studies in the UK, and who were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control (MenACWY) vaccine, provided upper airway swabs on a weekly basis and also if they developed symptoms of COVID-19 disease (a cough, a fever of 37?8?C or higher, shortness of breath, anosmia, or ageusia). Swabs were tested by nucleic acid ampli cation test (NAAT) for SARS-CoV-2 and positive samples were sequenced through the COVID-19 Genomics UK consortium. Neutralising antibody responses were measured using a live-virus microneutralisation assay against the B.1.1.7 lineage and a canonical non-B.1.1.7 lineage (Victoria). The e cacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to vaccine received. Vaccine e cacy was calculated as 1?relative risk (ChAdOx1 nCoV-19 vs MenACWY groups) derived from a robust Poisson regression model. This study is continuing and is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137.
Findings ...
PDF Format:
https://www.thelancet.com/journals/l...628-0/fulltext
DOI: https://doi.org/10.1016/S0140-6736(21)00628-0
Katherine R W Emary, FRCPath *, Tanya Golubchik, PhD *, Parvinder K Aley, DPhil , Cristina V Ariani, PhD , Brian Angus, MD , Sagida Bibi, PhD et al. Show all authors
Summary
Background
A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the e cacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant.
Methods
Volunteers (aged ?18 years) who were enrolled in phase 2/3 vaccine e cacy studies in the UK, and who were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control (MenACWY) vaccine, provided upper airway swabs on a weekly basis and also if they developed symptoms of COVID-19 disease (a cough, a fever of 37?8?C or higher, shortness of breath, anosmia, or ageusia). Swabs were tested by nucleic acid ampli cation test (NAAT) for SARS-CoV-2 and positive samples were sequenced through the COVID-19 Genomics UK consortium. Neutralising antibody responses were measured using a live-virus microneutralisation assay against the B.1.1.7 lineage and a canonical non-B.1.1.7 lineage (Victoria). The e cacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to vaccine received. Vaccine e cacy was calculated as 1?relative risk (ChAdOx1 nCoV-19 vs MenACWY groups) derived from a robust Poisson regression model. This study is continuing and is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137.
Findings ...
PDF Format:
https://www.thelancet.com/journals/l...628-0/fulltext